Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 6/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31362021 | 0.82 | MEN1 (0.46) | TAAR1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7116373 | 0.80 | KDM4E (0.47) | AOC3MAOBMAOAKDM4ETAAR1 | |
| SCHEMBL7116379 | 0.80 | KDM4E (0.47) | AOC3MAOBMAOAKDM4ETAAR1 | |
| SCHEMBL20371139 | 0.79 | TAAR1 (0.63) | AOC3MAOBMAOAKDM4ETAAR1 | |
| SCHEMBL6623381 | 0.77 | MAOB (0.46) | AOC3MAOBMAOAKDM4ETAAR1 | |
| SCHEMBL16609243 | 0.75 | CYP51A1 (0.42) | AOC3MAOBMAOAKDM4ETAAR1 | |
| SCHEMBL31361990 | 0.74 | ADRB3 (0.68) | MEN1KMT2ASMN1; SMN2ALDH1A1ADRB2 | |
| SCHEMBL7116376 | 0.74 | MEN1 (0.44) | AOC3MAOBMAOAKDM4ETAAR1 | |
| SCHEMBL7122412 | 0.72 | ADRB3 (0.46) | AOC3KDM4ETAAR1MEN1KMT2A | |
| SCHEMBL7694265 | 0.72 | ADRB3 (0.46) | AOC3KDM4ETAAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051295-A1 | PROCESS FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-02-13 | — | — | US | claimed |
| US-20250051295-A1 | PROCESS FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051295-A1 | PROCESS FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES | UGT1A6, UGT1A1, UGT1A3 | AOC3 2779/4885MAOB 1525/4885MAOA 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.